Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic Patients

Publisher： Karger

E-ISSN： 1421-9751|99|3|126-139

ISSN： 0008-6312

Source： Cardiology, Vol.99, Iss.3, 2003-06, pp. : 126-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical and genetic associations of autoantibodies to 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme a reductase in patients with immune‐mediated myositis and necrotizing myopathy

By  

MUSCLE AND NERVE, Vol. 52, Iss. 2, 2015-08 ,pp. : 196-203

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico

By Briseño Germán Gómez   Mino-León Dolores  

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1075-1081

Informa Healthcare

Access to resources Recommend Favorite

Application of multiplex ligation-dependent probe amplification, and identification of a heterozygous Alu-associated deletion and a uniparental disomy of chromosome 1 in two patients with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency

By                    

International Journal of Molecular Medicine, Vol. 35, Iss. 6, 2015-01 ,pp. : 1554-1560

Spandidos Publications

Access to resources Recommend Favorite

Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program

By  

Cardiology, Vol. 107, Iss. 4, 2007-03 ,pp. : 433-443

Karger

Access to resources Recommend Favorite

First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 315-324

John Wiley & Sons Inc

Access to resources Recommend Favorite